五养堂药业品牌怎么样 申请店铺

我要投票 五养堂药业在灵芝孢子粉行业中的票数:769 更新时间:2026-01-26
五养堂药业是哪个国家的品牌?「五养堂药业」是 浙江五养堂药业有限公司 旗下著名品牌。该品牌发源于浙江省丽水市,由创始人吴 * 谦在2004年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力五养堂药业品牌出海!将品牌入驻外推网,定制五养堂药业品牌推广信息,可以显著提高五养堂药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

五养堂药业怎么样

浙江五养堂药业有限公司使命是弘扬中医药五行养生文化,以现代生物科技制造灵芝、三叶青、铁皮石斛和红曲等道地药材的趁鲜口型中药饮片、保健食品、中药养生食品,以振兴中药保健食品产业和推动中药食疗食养、促进人类健康为己任,创新发展养肝(保肝明目)、养心(安心养神)、养脾(健脾益胃)、养肺(润肺养颜)、养肾(补肾益精)的五养系列健康产品,打造具有民族特色的中药保健养生和健康服务品牌。

浙江五养堂药业有限公司成立于2004年1月,其前身是浙江益圣菌物发展有限公司,由浙江省林业科学研究院、丽水市食用菌研究开发中心和吴学谦教授等40名自然人共同发起组建。2013年经严格的评估和公开挂牌交易,浙江省林业科学研究院的股份由吴学良等股东受让持有,国有股份全部退出,正式更名为“浙江五养堂药业有限公司”。

公司厂区占地面积20亩,建筑面积16000多平方米,建有中药饮片GMP车间、保健食品GMP车间、生物发酵车间、趁鲜冷冻超微破壁车间等四大健康产品生产线,目前是浙江省较大的灵芝破壁孢子粉、真菌多糖提取加工和三叶青口服型中药饮片趁鲜冷冻加工基地,产品远销欧美、日本、香港、台湾等国家和地区。

五养堂选育成功了“浙青1号“等新品种、掌握了三叶青的核心种植技术,已经申请了“一种果林地仿生套种袋式三叶青方法”等8项专利,通过三叶青趁鲜口服型加工技术改造和研发三叶青保健食品与抗菌抗炎退烧药品,拟从一产(规范种植)+二产(药品、保健食品加工)+三产(线上线下营销服务、健康服务、健康管理、健康保险、供应链管理)全产业链运作,将这一“天然的植物抗生素”三叶青产业做强做大。

五养堂将于2016年在新三板系统挂牌,并争取在1-2年内进入创新层,通过联合上市大企业搞定向增发,借助资本市场的力量将五养堂健康产业做强做大,实现百亿规模的企业梦想,并力求将五行中医药养生文化结合中国特色健康产品走向全世界。


The mission of Zhejiang wuyangtang Pharmaceutical Co., Ltd. is to carry forward the five elements health preservation culture of traditional Chinese medicine, to produce fresh Chinese herbal pieces, health food and health food of traditional Chinese medicine, such as Ganoderma lucidum, Trifolium, Dendrobium candidum and Monascus, with modern biotechnology, to revitalize the industry of health food of traditional Chinese medicine, promote the diet and nutrition of traditional Chinese medicine, and promote human health as its own duty, and innovate and develop the liver (liver protection Five series of health products, i.e. Mingmu, Yangxin (peace of mind and mind), yangpi (invigorating the spleen and stomach), Yangfei (moistening the lungs and beautifying the face) and Yangshen (invigorating the kidney and benefiting the essence), will build a brand of traditional Chinese medicine health care and health service with national characteristics. Zhejiang wuyangtang Pharmaceutical Co., Ltd. was founded in January 2004. Its predecessor is Zhejiang Yisheng fungus development Co., Ltd. which was jointly initiated and established by 40 natural persons including Zhejiang Academy of Forestry Sciences, Lishui edible fungus research and development center and Professor Wu Xueqian. In 2013, after strict evaluation and public listing, the shares of Zhejiang Academy of Forestry Sciences were transferred and held by Wu Xueliang and other shareholders, and all state-owned shares were withdrawn, officially renamed as "Zhejiang wuyangtang Pharmaceutical Co., Ltd.". The factory area of the company covers an area of 20 mu, with a building area of more than 16000 square meters. It has four major production lines for healthy products, including GMP workshop for Chinese herbal pieces, GMP workshop for health food, biological fermentation workshop, ultra-fine wall breaking workshop for fresh freezing. At present, it is a large base for the extraction and processing of Ganoderma lucidum wall breaking spore powder, fungal polysaccharide and Sanyeqing oral Chinese herbal pieces while fresh freezing in Zhejiang Province. The products are sold far Europe, America, Japan, Hong Kong, Taiwan and other countries and regions. Wuyangtang has successfully selected new varieties such as "zheqing No.1" and mastered the core planting technology of sanyeqin. It has applied for eight patents such as "a bionic interplanting bag type of sanyeqin in fruit forest". Through the technological transformation of sanyeqin taking advantage of the fresh oral processing technology and the research and development of sanyeqin health food and anti-bacterial, anti-inflammatory and fever reducing drugs, it is planned to produce from the first (standard planting) + the second (medicine, health food) Product processing) + three industries (online and offline marketing services, health services, health management, health insurance, supply chain management) operate in the whole industrial chain, making this "natural plant antibiotic" three leaf green industry stronger and bigger. Wuyangtang will be listed in the new three board system in 2016, and strive to enter the innovation layer within 1-2 years. Through joint listing of large enterprises to conduct targeted additional issuance, with the help of capital market, wuyangtang health industry will be stronger and bigger, and realize the enterprise dream of 10 billion scale, and strive to integrate the five elements of traditional Chinese medicine health culture with Chinese characteristics of health products to the world.

本文链接: https://brand.waitui.com/b6e82ab79.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

国产创新药里程碑款频获兑现 行业向可持续收益模式转型

国家药监局最新数据显示,2025年我国批准上市的创新药达76个,创历史新高。同时,创新药对外授权交易总金额超过1300亿美元,授权交易数量超过150笔。近期,国产创新药企的里程碑款捷报频传,表明中国创新药研发的价值得到验证。然而,过去由于里程碑款兑现率较低,业内常有“一次性BD”的诟病。如今,随着里程碑款的持续落地,行业正向可持续收益模式转型。(证券时报)

2小时前

多只理财产品业绩比较基准上限下调至不足3%

近期,农银理财、中邮理财、招银理财、上银理财等多家机构下调旗下理财产品业绩比较基准,部分产品最大降幅达100个基点。调整后,多数产品的业绩比较基准上限已不足3%,理财市场低收益新常态特征愈发凸显。受访专家表示,此次调整受市场利率环境变化与监管导向的驱动,后续业绩基准仍面临下行压力,但降幅会逐步收窄。(证券日报)

2小时前

华泰证券:市场或逐步切向业绩修复方向

36氪获悉,华泰证券研报认为,上周A股市场在资金情绪分化下,小盘股涨幅居前,行业轮动持续,向后看,资金面的弹性及后续轮动方向是市场主要关注点。研报认为1月中旬以来,宽基ETF流出金额虽偏高,但考虑到险资等仍有增量、投资者存在套利需求,市场持续放量下,资金侧仍有接力动能。轮动方向或由主题逐步切往存在业绩印证的方向,历史复盘来看,业绩预告披露期内的,景气具备持续修复能力的行业通常具备一定超额收益,具体到本轮,景气修复的线索或主要集中在涨价链、高端制造及AI链中,结合拥挤度进一步考量,配置上可关注电力设备、基础化工、半导体设备等,适度增配周期型红利。

2小时前

国泰君安国际:预期2025年度净利润为12.80亿至13.80亿港元之间,同比上升265%至293%

36氪获悉,国泰君安国际在港交所公告,预期本集团截至2025年12月31日止年度的净利润为12.80亿至13.80亿港元之间,较2024年净利润约3.51亿港元大幅飙升265%至293%。该预期增长的主要原因为本集团企业融资、财富管理、资产管理及交易及投资等核心业务收入全面大幅上升,其中股权融资及经纪业务表现尤为突出。

2小时前

开年迎3家公司上市,北交所总市值逼近万亿元规模

2026年以来,北交所迎来科马材料、爱舍伦、国亮新材三家公司上市,同时还有美德乐、农大科技两家公司进入发行流程。当前北交所正成为服务创新型中小企业的重要阵地。截至1月23日,北交所上市公司达290家,总市值9670.53亿元,逼近万亿元大关。与此同时,北交所IPO审核正保持高频节奏,多家券商认为,在北交所市场制度改革深化背景下,预计后续IPO有望维持高速发行态势。(中证网)

2小时前

本页详细列出关于五养堂药业的品牌信息,含品牌所属公司介绍,五养堂药业所处行业的品牌地位及优势。
咨询